ClinVar Miner

Submissions for variant NM_000327.4(ROM1):c.342C>T (p.Leu114=)

gnomAD frequency: 0.00049  dbSNP: rs537377404
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000396591 SCV000337874 likely benign not specified 2015-12-10 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV001105713 SCV001262709 benign Retinitis pigmentosa 2017-04-28 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign.
Labcorp Genetics (formerly Invitae), Labcorp RCV001517649 SCV001726187 benign not provided 2023-09-22 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV003920088 SCV004728293 likely benign ROM1-related disorder 2019-05-06 no assertion criteria provided clinical testing This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.